Scientific Advisory Board
Robert Guldberg, PhD
Robert Guldberg is the vice president and Robert and Leona DeArmond executive director of the Phil and Penny Knight Campus for Accelerating Scientific Impact at the University of Oregon. He holds bachelor’s, master’s, and doctoral degrees in mechanical engineering as well as a master’s degree in bioengineering, all from the University of Michigan. Guldberg also completed a postdoctoral fellowship in molecular biology at Michigan before joining the Georgia Institute of Technology in 1996. At Georgia Tech, Guldberg was a professor of mechanical and biomedical engineering, and served as executive director of the Parker H. Petit Institute for Bioengineering and Bioscience. His research in the areas of regenerative medicine, biomaterials, stem cell therapies, and orthopaedic medical devices is currently funded by the NIH, NSF, and DOD and has produced well over 200 publications to date. Over his 20+ year academic career, Dr. Guldberg has served as an advisor and board member for numerous biotechnology companies, patented several technologies, and co-founded four start-ups. At the national level, Dr. Guldberg has held several leadership positions, including President of the Americas Chapter of the Tissue Engineering and Regenerative Medicine International Society (TERMIS-AM).
Warren Grunderfest, MD, PhD
Dr. Grundfest is a professor of Biomedical Engineering, Electrical Engineering and Surgery at UCLA. He is also the Senior West Coast Advisor and Portfolio Manager for Biomaterials and Nanomaterials at TATRC US Army. Dr. Grundfest has a BA from Swarthmore College, an MD from Columbia University and did his general surgery residency at UCLA. He was the General Surgery Chief resident at Cedars-Sinai Medical Center from 1982-1985.
Dr. Paul Wan DVM DACVS
Paul Wan is a Broad Certified Equine Surgeon and owner of SoCal Equine Hospital. Dr. Wan has more than 15 years experience in all major fields of surgery, including soft tissue, orthopedics, laparoscopic, and laser. He specializes in equine lameness diagnosis and treatment. As a Medicus advisory board member, Dr. Wan performs feasibility assessments and early proof of concept work for Medicus products for the equine industry. He performed the early feasibility and safety work on the use of the HyFlex technology in the equine joint and skin, and the use of HyFlex as a "paint on" drug delivery vehicle for the treatment of equine sarcoids and squamous cell carcinoma. Dr. Wan is an active member of AVMA, ACVS, AAEP, CVMA, and ISLEP.